Scarica l'app Stockscreener
29.36
3.16%
0.90
Precedente Chiudi:
$28.46
Aprire:
$28.4
Volume 24 ore:
827.87K
Relative Volume:
0.54
Capitalizzazione di mercato:
$4.05B
Reddito:
$10.12M
Utile/perdita netta:
$-280.49M
Rapporto P/E:
-10.16
EPS:
-2.89
Flusso di cassa netto:
$-188.51M
1 W Prestazione:
-1.81%
1M Prestazione:
-11.49%
6M Prestazione:
-5.84%
1 anno Prestazione:
-24.33%
Intervallo 1D:
$28.15
$29.57
Intervallo di 1 settimana:
$27.70
$30.52
Portata 52W:
$21.51
$56.00
Avidity Biosciences Inc Stock (RNA) Company Profile
Nome
Avidity Biosciences Inc
Settore
Industria
Telefono
858-401-7900
Indirizzo
10578 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Confronta RNA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RNA
Avidity Biosciences Inc
|
29.36 | 4.05B | 10.12M | -280.49M | -188.51M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Avidity Biosciences Inc Stock (RNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-11 | Iniziato | Raymond James | Strong Buy |
| 2025-03-13 | Iniziato | Citigroup | Buy |
| 2025-03-12 | Iniziato | BMO Capital Markets | Outperform |
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2024-12-20 | Iniziato | H.C. Wainwright | Buy |
| 2024-11-26 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-09-24 | Iniziato | Goldman | Buy |
| 2024-08-28 | Iniziato | Barclays | Overweight |
| 2024-05-03 | Iniziato | BofA Securities | Buy |
| 2024-03-14 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-05-22 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-03-31 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-07-20 | Iniziato | Chardan Capital Markets | Buy |
| 2022-07-12 | Iniziato | Raymond James | Strong Buy |
| 2021-09-07 | Iniziato | Evercore ISI | Outperform |
| 2021-06-17 | Iniziato | Needham | Buy |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2020-07-07 | Iniziato | Cowen | Outperform |
| 2020-07-07 | Iniziato | Credit Suisse | Outperform |
| 2020-07-07 | Iniziato | SVB Leerink | Outperform |
| 2020-07-07 | Iniziato | Wells Fargo | Overweight |
Mostra tutto
Avidity Biosciences Inc Borsa (RNA) Ultime notizie
Avidity Biosciences’ SWOT analysis: innovative RNA firm eyes 3-drug launch by 2027 - Investing.com
Wolfe Research Initiates Coverage on Avidity Biosciences (RNA) with 'Outperform' Rating | RNA Stock News - GuruFocus
Avidity Biosciences (RNA) Receives Outperform Rating Amid Biotec - GuruFocus
Why Avidity Biosciences Shares Are Under the Spotlight - TipRanks
Wolfe Research Initiates Coverage on Avidity Biosciences With Outperform Rating, $55 Price Target - MarketScreener
Avidity Biosciences (RNA) Receives Outperform Rating Amid Biotech Advancements | RNA Stock News - GuruFocus
(RNA) Proactive Strategies - news.stocktradersdaily.com
Avidity Biosciences (RNA) Receives Outperform Rating from Wolfe Research | RNA Stock News - GuruFocus
The week in pharma: action, reaction and insight – week to June 13 - The Pharma Letter
Avidity Biosciences’ SWOT analysis: innovative RNA tech targets rare disease stock potential - Investing.com Australia
Avidity Biosciences’ SWOT analysis: innovative RNA tech targets rare disease stock potential By Investing.com - Investing.com South Africa
Avidity Biosciences chief scientific officer sells $657,694 in stock - Investing.com Australia
Avidity Biosciences, Inc. (RNA) Initiated with a Strong Buy at Raymond James - MSN
Avidity Biosciences chief scientific officer sells $657,694 in stock By Investing.com - Investing.com South Africa
13 Biotech Stocks with Huge Upside Potential - Insider Monkey
Avidity Biosciences (RNA) Receives Strong Buy Rating from Raymond James | RNA Stock News - GuruFocus
Avidity Biosciences to Present Topline Data from Phase 1/2 FORTITUDE™ Trial of Del-brax in People Living with Facioscapulohumeral Muscular Dystrophy at 32nd Annual FSHD Society International Research Congress – Company AnnouncementFT.com - Financial Times
Raymond James Initiates Coverage of Avidity Biosciences (RNA) with Strong Buy Recommendation - MSN
Avidity Biosciences holds annual stockholders meeting By Investing.com - Investing.com South Africa
Avidity Biosciences Holds 2025 Annual Stockholder Meeting - TipRanks
Avidity Biosciences holds annual stockholders meeting - Investing.com
Avidity Biosciences price target raised to $75 from $65 at Chardan - Yahoo Finance
JP Morgan Raises Price Target for Avidity Biosciences (RNA) to $59 | RNA Stock News - GuruFocus
The Analyst Verdict: Avidity Biosciences In The Eyes Of 12 Experts - Nasdaq
Avidity Biosciences (RNA) Sees Price Target Increase Amid Promis - GuruFocus
Avidity Biosciences (RNA) Gains Boost with New Price Target and Accelerated Approval Path | RNA Stock News - GuruFocus
Barclays Raises Target Price for Avidity Biosciences (RNA) | RNA Stock News - GuruFocus
Avidity Biosciences (RNA) Price Target Raised Amid Positive Deve - GuruFocus
RNA: Avidity Biosciences Maintains Buy Rating with Price Target Increase | RNA Stock News - GuruFocus
Avidity reports promising FSHD therapy trial results By Investing.com - Investing.com South Africa
Avidity Biosciences Announces the Accelerated Approval Regulatory Pathway in the U.S. is Open for Del-Brax and Initiates the Global, Confirmatory Phase 3 FORWARD™ Study in FSHD - StreetInsider
Avidity Biosciences (RNA) Seeks Accelerated Approval for Key Drug | RNA Stock News - GuruFocus
Avidity Biosciences stock falls following positive trial data By Investing.com - Investing.com Canada
Avidity Biosciences stock falls following positive trial data - Investing.com
BofA lifts Avidity Biosciences stock target to $54 By Investing.com - Investing.com Canada
Avidity Biosciences Touts Encouraging Functional Gains And Biomarker Reductions In Rare Muscular Weakness Disease Trial - Yahoo
Avidity Biosciences (RNA) Price Target Raised Amid Positive Developments | RNA Stock News - GuruFocus
Avidity Biosciences (RNA) Receives Enhanced Price Target Followi - GuruFocus
Transcript : Avidity Biosciences, Inc.Shareholder/Analyst Call - MarketScreener
Avidity Biosciences (RNA) Receives Enhanced Price Target Following Trial Results | RNA Stock News - GuruFocus
Avidity Biosciences Shares Face Turbulence Amid Mixed Signals - TipRanks
Avidity Biosciences (RNA) Reports Promising Results from FSHD Treatment Study | RNA Stock News - GuruFocus
Avidity Biosciences (RNA) Advances Del-brax Approval Pathway for FSHD Treatment | RNA Stock News - GuruFocus
Avidity Reports Positive Phase 1/2 Data For Del-Brax In FSHD Patients - MarketScreener
Avidity reports promising FSHD therapy trial results - Investing.com
Breakthrough FSHD Drug Trial Success: First-Ever Treatment Shows Multiple Improvements in Muscle Disease - Stock Titan
Avidity Biosciences Announces the Accelerated Approval Regulatory Pathway in the U.S. is Open for Del-Brax and Initiates the Global, Confirmatory Phase 3 FORWARD™ Study in FSHD – Company Announcement - Financial Times
Stocks Flashing Renewed Technical Strength: Avidity Biosciences - Investor's Business Daily
(RNA) Investment Analysis - news.stocktradersdaily.com
Avidity Biosciences’ SWOT analysis: innovative muscle therapy stock faces hurdles - Investing.com Nigeria
Myotonic Dystrophy Market to Expand Significantly by 2034, - openPR.com
Avidity Biosciences Inc Azioni (RNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.45%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):